862822-06-8

Basic information

• Product Name: (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester
• Synonyms: (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester
• CAS NO: 862822-06-8
• Molecular Formula: C₁₂H₁₃N₃O₄S
• Molecular Weight: 295.31432
• EINECS: -0
• Mol File: 862822-06-8.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester(862822-06-8)
• EPA Substance Registry System: (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester(862822-06-8)

Safety Data

• Hazardous Substances Data: 862822-06-8(Hazardous Substances Data)

Usage

General Description

In (6-Nitro-benzothiazol-2-yl)-carbaMic acid tert-butyl ester, the primary component is carbaMic acid, which is a carbamate derivative. The compound also contains a tert-butyl ester group, which is commonly used to protect the carboxylic acid functionality in organic synthesis. The presence of a nitro group in the benzothiazole ring adds an electron-withdrawing property to the molecule, making it potentially useful in pharmacological and chemical applications. Overall, this compound is a combination of a carbamate derivative and a benzothiazole derivative with a tert-butyl ester group, and its properties and potential applications can be attributed to these functional groups.

Upstream product

• 6285-57-0 2-amino-6-nitrobenzothiazole 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 862821-93-0 [6-(2,6-dichloro-benzoylamino)-benzothiazol-2-yl]-carbamic acid tert-butyl ester 
• 862822-08-0 N-(2-amino-benzothiazol-6-yl)-2,6-dichloro-benzamide 
• 862822-07-9 (6-aminobenzothiazol-2-yl)carbamic acid tert-butyl ester 

Relevant articles and documents

Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects

Inhibition of the soluble epoxide hydrolase (sEH) is a promising new therapeutic approach in the treatment of inflammation. Driven by the in-house database product lead 1, a hybridization strategy was utilized for the design of a series of novel benzo [d]thiazol derivatives. To our delight, D016, a byproduct of compound 9, was obtained with an extraordinarily low IC50 value of 0.1 nM but poor physical and chemical properties. After removal of a non-essential urea moiety or replacement of the urea group by an amide group, compounds 15a, 17p, and 18d were identified as promising sEH inhibitors, and their molecular binding modes to sEH were constructed. Furthermore, compounds 15a and 18d exhibited more effective in vivo anti-inflammatory effect than t-AUCB in carrageenan-induced mouse paw edema. Compound 15a also showed moderate metabolic stability with a half-time of 34.7 min. Although 18d was unstable in rat liver microsomes, it might be a “prodrug”. In conclusion, this study could provide valuable insights into discovery of new sEH inhibitors, and compounds 15a and 18d were worthy of further development as potential drug candidates to treat inflammation.

Selective sodium channel regulator as well as preparation and application thereof

The invention provides a compound serving as a selective sodium channel regulator and a synthesis and use method, and particularly provides a compound shown as a formula (I), a preparation method of the compound and application of the compound serving as the selective sodium channel regulator. The compounds exhibit excellent activity as a regulator of sodium channels.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.